- Home
- ACHL vs FBIO Comparison
ACHL vs FBIO Comparison
Compare ACHL & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHL
- FBIO
- Stock Information
- Founded
- ACHL 2016
- FBIO 2006
- Country
- ACHL United Kingdom
- FBIO United States
- Employees
- ACHL N/A
- FBIO N/A
- Industry
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ACHL Health Care
- FBIO Health Care
- Exchange
- ACHL Nasdaq
- FBIO Nasdaq
- Market Cap
- ACHL 43.6M
- FBIO 39.4M
- IPO Year
- ACHL 2021
- FBIO N/A
- Fundamental
- Price
- ACHL $0.95
- FBIO $1.77
- Analyst Decision
- ACHL Buy
- FBIO Strong Buy
- Analyst Count
- ACHL 2
- FBIO 3
- Target Price
- ACHL $4.00
- FBIO $18.00
- AVG Volume (30 Days)
- ACHL 107.8K
- FBIO 699.0K
- Earning Date
- ACHL 11-14-2024
- FBIO 11-14-2024
- Dividend Yield
- ACHL N/A
- FBIO N/A
- EPS Growth
- ACHL N/A
- FBIO N/A
- EPS
- ACHL N/A
- FBIO N/A
- Revenue
- ACHL N/A
- FBIO $81,501,000.00
- Revenue This Year
- ACHL N/A
- FBIO N/A
- Revenue Next Year
- ACHL N/A
- FBIO $134.70
- P/E Ratio
- ACHL N/A
- FBIO N/A
- Revenue Growth
- ACHL N/A
- FBIO 31.51
- 52 Week Low
- ACHL $0.63
- FBIO $1.36
- 52 Week High
- ACHL $1.76
- FBIO $4.43
- Technical
- Relative Strength Index (RSI)
- ACHL 29.24
- FBIO 43.63
- Support Level
- ACHL $0.97
- FBIO $1.41
- Resistance Level
- ACHL $1.01
- FBIO $2.27
- Average True Range (ATR)
- ACHL 0.03
- FBIO 0.18
- MACD
- ACHL -0.01
- FBIO -0.04
- Stochastic Oscillator
- ACHL 0.87
- FBIO 8.06
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.